JP2012526803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526803A5 JP2012526803A5 JP2012510756A JP2012510756A JP2012526803A5 JP 2012526803 A5 JP2012526803 A5 JP 2012526803A5 JP 2012510756 A JP2012510756 A JP 2012510756A JP 2012510756 A JP2012510756 A JP 2012510756A JP 2012526803 A5 JP2012526803 A5 JP 2012526803A5
- Authority
- JP
- Japan
- Prior art keywords
- aminophenyl
- methyl
- benzamide
- oxoisoindoline
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 84
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 claims description 68
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 60
- -1 amide compound Chemical class 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 5
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 3
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims description 3
- APSTWUQDOVMXOZ-UHFFFAOYSA-N 4-[[7-(3-acetamidophenyl)-3-oxo-1h-isoindol-2-yl]methyl]-n-(2-aminophenyl)benzamide Chemical compound CC(=O)NC1=CC=CC(C=2C=3CN(CC=4C=CC(=CC=4)C(=O)NC=4C(=CC=CC=4)N)C(=O)C=3C=CC=2)=C1 APSTWUQDOVMXOZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- LYHZVZOXCVEZLV-UHFFFAOYSA-N n-(2-aminophenyl)-4-[(3-oxo-6-pyridin-3-yl-1h-isoindol-2-yl)methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CN1C(=O)C2=CC=C(C=3C=NC=CC=3)C=C2C1 LYHZVZOXCVEZLV-UHFFFAOYSA-N 0.000 claims description 2
- YFKZHVYJZWLAID-UHFFFAOYSA-N n-(2-aminophenyl)-4-[(3-oxo-6-pyrimidin-5-yl-1h-isoindol-2-yl)methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CN1C(=O)C2=CC=C(C=3C=NC=NC=3)C=C2C1 YFKZHVYJZWLAID-UHFFFAOYSA-N 0.000 claims description 2
- FADRSVQBYKMIQN-UHFFFAOYSA-N n-(2-aminophenyl)-4-[(3-oxo-7-pyridin-3-yl-1h-isoindol-2-yl)methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CN1C(=O)C(C=CC=C2C=3C=NC=CC=3)=C2C1 FADRSVQBYKMIQN-UHFFFAOYSA-N 0.000 claims description 2
- CSIHFGREVUCTLK-UHFFFAOYSA-N n-(2-aminophenyl)-4-[(3-oxo-7-pyrimidin-5-yl-1h-isoindol-2-yl)methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CN1C(=O)C(C=CC=C2C=3C=NC=NC=3)=C2C1 CSIHFGREVUCTLK-UHFFFAOYSA-N 0.000 claims description 2
- KIPJIVDSUCESGM-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[3-oxo-7-(4-phenoxyphenyl)-1h-isoindol-2-yl]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CN1C(=O)C(C=CC=C2C=3C=CC(OC=4C=CC=CC=4)=CC=3)=C2C1 KIPJIVDSUCESGM-UHFFFAOYSA-N 0.000 claims description 2
- OZJARHJCNXYKJQ-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[3-oxo-7-(4-phenylphenyl)-1h-isoindol-2-yl]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CN1C(=O)C(C=CC=C2C=3C=CC(=CC=3)C=3C=CC=CC=3)=C2C1 OZJARHJCNXYKJQ-UHFFFAOYSA-N 0.000 claims description 2
- LBAHPAGTDLXSBT-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[6-(4-cyanophenyl)-3-oxo-1h-isoindol-2-yl]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CN1C(=O)C2=CC=C(C=3C=CC(=CC=3)C#N)C=C2C1 LBAHPAGTDLXSBT-UHFFFAOYSA-N 0.000 claims description 2
- HXRBEWCWHLXIQT-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[7-(4-cyanophenyl)-3-oxo-1h-isoindol-2-yl]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CN1C(=O)C(C=CC=C2C=3C=CC(=CC=3)C#N)=C2C1 HXRBEWCWHLXIQT-UHFFFAOYSA-N 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 206010017076 Fracture Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001548 androgenic effect Effects 0.000 claims 1
- 230000008468 bone growth Effects 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 4
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- IJVLKUUJKWFLNT-UHFFFAOYSA-N 3-(2,4-dimethoxyphenyl)-n-[6-(hydroxyamino)-6-oxohexyl]-2-methylbenzamide Chemical compound COC1=CC(OC)=CC=C1C1=CC=CC(C(=O)NCCCCCC(=O)NO)=C1C IJVLKUUJKWFLNT-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- GPRGHRLPSXZHCX-UHFFFAOYSA-N 6-[6-(3,5-difluorophenyl)-3-oxo-1h-isoindol-2-yl]-n-hydroxyhexanamide Chemical compound C=1C=C2C(=O)N(CCCCCC(=O)NO)CC2=CC=1C1=CC(F)=CC(F)=C1 GPRGHRLPSXZHCX-UHFFFAOYSA-N 0.000 description 1
- AMEODNRBRYGFEK-UHFFFAOYSA-N 6-[7-(3,5-difluorophenyl)-3-oxo-1h-isoindol-2-yl]-n-hydroxyhexanamide Chemical compound O=C1N(CCCCCC(=O)NO)CC2=C1C=CC=C2C1=CC(F)=CC(F)=C1 AMEODNRBRYGFEK-UHFFFAOYSA-N 0.000 description 1
- PTDIDDUASZGWJU-UHFFFAOYSA-N CCCCCC(NN(CC(C1=CC=C2)=C2Br)C1=O)=O Chemical compound CCCCCC(NN(CC(C1=CC=C2)=C2Br)C1=O)=O PTDIDDUASZGWJU-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- MKRLOYGAMDADCY-UHFFFAOYSA-N n-(2-aminophenyl)-6-(3-oxo-7-pyridin-3-yl-1h-isoindol-2-yl)hexanamide Chemical compound NC1=CC=CC=C1NC(=O)CCCCCN1C(=O)C(C=CC=C2C=3C=NC=CC=3)=C2C1 MKRLOYGAMDADCY-UHFFFAOYSA-N 0.000 description 1
- ONKPXXLEOCVXSX-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-2-methyl-3-phenylbenzamide Chemical compound CC1=C(C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)C=CC=C1C1=CC=CC=C1 ONKPXXLEOCVXSX-UHFFFAOYSA-N 0.000 description 1
- IYBLDDMWCACMSU-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-2-methyl-3-pyridin-3-ylbenzamide Chemical compound CC1=C(C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)C=CC=C1C1=CC=CN=C1 IYBLDDMWCACMSU-UHFFFAOYSA-N 0.000 description 1
- QXUSPNJEPXHZFJ-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-2-methyl-3-pyridin-4-ylbenzamide Chemical compound CC1=C(C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)C=CC=C1C1=CC=NC=C1 QXUSPNJEPXHZFJ-UHFFFAOYSA-N 0.000 description 1
- XVBOZQPOGMIZKG-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-3-bromo-2-methylbenzamide Chemical compound CC1=C(Br)C=CC=C1C(=O)NCCCCCC(=O)NC1=CC=CC=C1N XVBOZQPOGMIZKG-UHFFFAOYSA-N 0.000 description 1
- UPSIJSSOIMGMRG-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-3-methyl-4-phenylbenzamide Chemical compound CC1=CC(C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)=CC=C1C1=CC=CC=C1 UPSIJSSOIMGMRG-UHFFFAOYSA-N 0.000 description 1
- OTEVANIASIXPMY-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-3-methyl-4-pyridin-3-ylbenzamide Chemical compound CC1=CC(C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)=CC=C1C1=CC=CN=C1 OTEVANIASIXPMY-UHFFFAOYSA-N 0.000 description 1
- PUXLIDVSFRGNKD-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-3-methyl-4-pyridin-4-ylbenzamide Chemical compound CC1=CC(C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)=CC=C1C1=CC=NC=C1 PUXLIDVSFRGNKD-UHFFFAOYSA-N 0.000 description 1
- NDOQOYMXQCHYNP-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-3-methyl-4-pyrimidin-5-ylbenzamide Chemical compound CC1=CC(C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)=CC=C1C1=CN=CN=C1 NDOQOYMXQCHYNP-UHFFFAOYSA-N 0.000 description 1
- XXTLYNLIXHSTNO-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-4-(2,4-dimethoxyphenyl)-3-methylbenzamide Chemical compound COC1=CC(OC)=CC=C1C1=CC=C(C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)C=C1C XXTLYNLIXHSTNO-UHFFFAOYSA-N 0.000 description 1
- DWXYWTQUHQDVML-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-4-(3,5-dimethylphenyl)-3-methylbenzamide Chemical compound CC1=CC(C)=CC(C=2C(=CC(=CC=2)C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)C)=C1 DWXYWTQUHQDVML-UHFFFAOYSA-N 0.000 description 1
- GJOQYAQQJLSJTO-UHFFFAOYSA-N n-[6-(2-aminoanilino)-6-oxohexyl]-4-bromo-3-methylbenzamide Chemical compound C1=C(Br)C(C)=CC(C(=O)NCCCCCC(=O)NC=2C(=CC=CC=2)N)=C1 GJOQYAQQJLSJTO-UHFFFAOYSA-N 0.000 description 1
- ZJJQGVOFSMFSJP-UHFFFAOYSA-N n-[6-(hydroxyamino)-6-oxohexyl]-2-methyl-3-phenylbenzamide Chemical compound CC1=C(C(=O)NCCCCCC(=O)NO)C=CC=C1C1=CC=CC=C1 ZJJQGVOFSMFSJP-UHFFFAOYSA-N 0.000 description 1
- IQSVCTXOPFGMPJ-UHFFFAOYSA-N n-[6-(hydroxyamino)-6-oxohexyl]-3-methyl-4-phenylbenzamide Chemical compound CC1=CC(C(=O)NCCCCCC(=O)NO)=CC=C1C1=CC=CC=C1 IQSVCTXOPFGMPJ-UHFFFAOYSA-N 0.000 description 1
- XCCGRSGMQOTYQD-UHFFFAOYSA-N n-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]-2-methyl-3-phenylbenzamide Chemical compound CC1=C(C(=O)NCC=2C=CC(=CC=2)C(=O)NC=2C(=CC=CC=2)N)C=CC=C1C1=CC=CC=C1 XCCGRSGMQOTYQD-UHFFFAOYSA-N 0.000 description 1
- OPNRMJUNSYQVSW-UHFFFAOYSA-N n-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]-3-bromo-2-methylbenzamide Chemical compound CC1=C(Br)C=CC=C1C(=O)NCC1=CC=C(C(=O)NC=2C(=CC=CC=2)N)C=C1 OPNRMJUNSYQVSW-UHFFFAOYSA-N 0.000 description 1
- QHWLEVLLYKCVAB-UHFFFAOYSA-N n-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]-3-bromo-4,5-dimethoxy-2-methylbenzamide Chemical compound BrC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(=CC=2)C(=O)NC=2C(=CC=CC=2)N)=C1C QHWLEVLLYKCVAB-UHFFFAOYSA-N 0.000 description 1
- PRKAQBQNEYQMQX-UHFFFAOYSA-N n-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]-4,5-dimethoxy-2-methyl-3-phenylbenzamide Chemical compound CC=1C(C=2C=CC=CC=2)=C(OC)C(OC)=CC=1C(=O)NCC(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N PRKAQBQNEYQMQX-UHFFFAOYSA-N 0.000 description 1
- AJCQTXMBEDIFOV-UHFFFAOYSA-N n-hydroxy-6-[3-oxo-6-[4-(trifluoromethyl)phenyl]-1h-isoindol-2-yl]hexanamide Chemical compound C=1C=C2C(=O)N(CCCCCC(=O)NO)CC2=CC=1C1=CC=C(C(F)(F)F)C=C1 AJCQTXMBEDIFOV-UHFFFAOYSA-N 0.000 description 1
- IGKUBBOXCUWRIB-UHFFFAOYSA-N n-hydroxy-6-[3-oxo-7-[4-(trifluoromethyl)phenyl]-1h-isoindol-2-yl]hexanamide Chemical compound O=C1N(CCCCCC(=O)NO)CC2=C1C=CC=C2C1=CC=C(C(F)(F)F)C=C1 IGKUBBOXCUWRIB-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2009-0042585 | 2009-05-15 | ||
| KR10-2009-0042691 | 2009-05-15 | ||
| KR1020090042585A KR20100123379A (ko) | 2009-05-15 | 2009-05-15 | 벤즈아마이드 유도체, 이의 제조방법 및 이를 포함하는 골 질환의 예방 및 치료용 약학 조성물 |
| KR1020090042691A KR101142053B1 (ko) | 2009-05-15 | 2009-05-15 | 이소인돌리논 유도체, 이의 제조방법 및 이를 포함하는 약학 조성물 |
| PCT/KR2010/003060 WO2010131922A2 (en) | 2009-05-15 | 2010-05-14 | Amide compound, preparation method thereof and pharmaceutical composition comprising same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526803A JP2012526803A (ja) | 2012-11-01 |
| JP2012526803A5 true JP2012526803A5 (https=) | 2014-09-11 |
| JP5713999B2 JP5713999B2 (ja) | 2015-05-07 |
Family
ID=43085472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510756A Expired - Fee Related JP5713999B2 (ja) | 2009-05-15 | 2010-05-14 | アミド化合物、その製造方法及びそれを含む薬学組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8716326B2 (https=) |
| EP (1) | EP2429987A4 (https=) |
| JP (1) | JP5713999B2 (https=) |
| WO (1) | WO2010131922A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009289649B2 (en) | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| PH12012501492B1 (en) * | 2010-01-22 | 2020-01-24 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US9540395B2 (en) | 2011-02-28 | 2017-01-10 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| CN102850236B (zh) * | 2011-06-27 | 2016-05-18 | 国药一心制药有限公司 | 新型苯甲酰胺类组蛋白去乙酰化酶抑制剂及其应用 |
| EP2734500A4 (en) | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| DK2970139T3 (en) | 2013-03-15 | 2018-08-13 | Biomarin Pharm Inc | HDAC inhibitors |
| EP2801569A1 (en) * | 2013-05-09 | 2014-11-12 | Ikerchem, S.L. | Histone deacetylase inhibitors based on derivatives of tricyclic polyhydroacridine and analogs possessing fused saturated five- and seven-membered rings |
| WO2015054099A1 (en) | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| WO2015084905A1 (en) | 2013-12-03 | 2015-06-11 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| JP6952602B2 (ja) | 2014-07-07 | 2021-10-20 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | ヒストンデアセチラーゼ阻害剤による白血病の治療 |
| US9937174B2 (en) | 2014-12-05 | 2018-04-10 | University of Modena and Reggio Emilia | Combinations of histone deacetylase inhibitors and bendamustine |
| EP3303306B1 (en) | 2015-06-08 | 2020-02-12 | Acetylon Pharmaceuticals, Inc. | Crystalline forms of a histone deacetylase inhibitor |
| JP6873053B2 (ja) | 2015-06-08 | 2021-05-19 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | タンパク質脱アセチル化阻害剤の製造方法 |
| HUE068392T2 (hu) | 2015-10-21 | 2024-12-28 | Otsuka Pharma Co Ltd | Benzolaktám vegyületek mint fehérje kináz gátlók |
| US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
| ES2929032T3 (es) | 2016-08-08 | 2022-11-24 | Acetylon Pharmaceuticals Inc | Combinaciones farmacéuticas de inhibidores de histona desacetilasa 6 y anticuerpos inhibidores de CD20 y usos de los mismos |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4077998A (en) * | 1975-10-28 | 1978-03-07 | Morton-Norwich Products, Inc. | Phthaloyl amino acid hydroxamic acids |
| KR100194535B1 (ko) * | 1995-12-27 | 1999-06-15 | 우종일 | 아릴 벤조일 우레아 유도체 및 이를 함유하는 농약조성물 |
| KR100194534B1 (ko) * | 1996-06-29 | 1999-06-15 | 우종일 | 2-클로로-3,5-비스 (트피플루오르메틸) 페닐 벤조일 우레아 유도체 및 이의 제조방법 |
| US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| EP1024134A4 (en) * | 1997-10-09 | 2003-05-14 | Ono Pharmaceutical Co | DERIVATIVES OF AMINOBUTANIC ACID |
| EP1335898B1 (en) | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
| JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| US7868204B2 (en) * | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US20050215601A1 (en) * | 2002-09-25 | 2005-09-29 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient |
| EP1738752A1 (en) * | 2002-12-27 | 2007-01-03 | Schering Aktiengesellschaft | Pharmaceutical combinations comprising cis-retine acid |
| JP4939941B2 (ja) * | 2003-08-26 | 2012-05-30 | 株式會社アモーレパシフィック | ヒドロキサム酸誘導体及びその製造方法 |
| CN101115495B (zh) * | 2004-12-14 | 2011-06-22 | 生物如恩克斯株式会社 | 通过runx2乙酰化作用增强bmp的骨形成活性的方法 |
| US20100278782A1 (en) * | 2006-06-12 | 2010-11-04 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
| AU2008269154B2 (en) * | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| AU2009289649B2 (en) | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
-
2010
- 2010-05-14 EP EP10775124A patent/EP2429987A4/en not_active Withdrawn
- 2010-05-14 US US13/320,117 patent/US8716326B2/en not_active Expired - Fee Related
- 2010-05-14 JP JP2012510756A patent/JP5713999B2/ja not_active Expired - Fee Related
- 2010-05-14 WO PCT/KR2010/003060 patent/WO2010131922A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526803A5 (https=) | ||
| JP2007519754A5 (https=) | ||
| RU2205827C2 (ru) | Производное ацилпиперазинилпиримидина, способы его получения, фармацевтическая композиция | |
| RU2423354C2 (ru) | Соединения и композиции - модуляторы сигнального пути hedgehog | |
| WO2010131922A4 (en) | Amide compound, preparation method thereof and pharmaceutical composition comprising same | |
| HRP20181076T1 (hr) | Pirazolski derivati kao modulatori kalcijevih kanala aktiviranih oslobađanjem kalcija | |
| HRP20160118T1 (hr) | HETEROCIKLIÄŚKI DERIVAT KAO INHIBITOR MIKROSOMSKIH SINTAZA PROSTAGLANDINA E (mPGEs) | |
| JP2013507350A5 (https=) | ||
| JP2010513444A5 (https=) | ||
| JP2007519735A5 (https=) | ||
| RU2010138639A (ru) | Бициклические амиды как ингибиторы киназы | |
| JP2014511869A5 (https=) | ||
| RU2004129780A (ru) | Производные аминоиндазолов, способ получения и промежуточные продукты этого способа в качестве лекарственных средств и содержащие их фармацевтические композиции | |
| SI2970155T1 (en) | INHIBITORS INDOLEAMIN 2,3-DIOXYGENESIS (IDO) | |
| JP2008542279A5 (https=) | ||
| JP2010514677A5 (https=) | ||
| JP2012510989A5 (https=) | ||
| JP2009526072A5 (https=) | ||
| RU2009116670A (ru) | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина | |
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| HRP20151201T1 (hr) | Supstituirani derivati benzamida | |
| ME00427B (me) | N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze | |
| JP2013501720A5 (https=) | ||
| HRP20130865T1 (hr) | Derivati pirazol piridina kao inhibitori nadph oksidaze |